Saphyr Provides Full Structural Variation Evaluation in Reliable Tumors, Enables Discovery of Novel Diagnostic Markers and Drug Targets
6 min read-
Preliminary readout on Saphyr validation study for brain cancer presents path to sound tumor LDT
-
Saphyr outperforms Oncoscan array for structural variation and copy range variation detection in strong tumors
-
Saphyr delivers complete and obvious photo of structural variation in solid tumors, which has not been achievable to day with NGS or array
-
Saphyr provides big opportunity for discovery of new therapeutic targets and prognostic markers in cancer
SAN DIEGO, Jan. 14, 2021 (Globe NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) announced that working day 3 of its 5-day Up coming-Technology Cytogenomics Symposium featured six Saphyr people presenting their outcomes and experiences working with the Saphyr® procedure for optical genome mapping (OGM) to evaluate reliable tumor genomes. The presentations by scientists and clinicians from top hospitals and health care investigation establishments in Europe and the US talked about benefits on a selection of strong tumors these as cancers of the head and neck, brain, breast, liver, and the eye. All six experiments confirmed that Saphyr allows for the initially time a finish and clear picture of structural variation in the genome and gives opportunity for the discovery of novel most cancers drivers, therapeutic targets, and prognostic markers, something which has not been feasible to day with upcoming-generation sequencing (NGS) and array platforms.
Dr. Jim Broach, Director of the Penn Point out Institute for Personalized Medicine presented on HPV-induced head and neck most cancers, just one of the couple cancers on the rise in the US although most other cancers carry on to decrease. OGM authorized his group to reconstruct sophisticated genomic improvements that future-technology sequencing hasn’t been ready to recognize. He concluded that Saphyr is a effective tool to discover and characterize viral integration in tumors and that it can detect the genome instability affiliated with HPV integration.
Dr. Adrian Lee, Director of the Institute for Precision Drugs at the University of Pittsburgh introduced on his use of OGM to analyze invasive lobular breast cancer, the sixth most popular most cancers in women of all ages. Applying Saphyr, he was in a position to reconstruct really elaborate chromosome-wide rearrangements as perfectly as clinically important single gene deletions. He stated that most cancers genomics has long concentrated on modest issue mutations only for the reason that the structural variants (SVs) ended up not obtainable with next-era sequencing tools, and he believes that OGM will allow for the discovery of therapeutic targets and diagnostic markers from SV details. He concluded that substantial structural variants are frequent in breast cancer and have essential clinical worth, that Saphyr can detect duplicate amount modifications as properly as the conventional one nucleotide polymorphism (SNP) arrays and that on top of that it can detect all other SV styles genome-broad as perfectly.
Dr. Justin Balko, Vanderbilt College Medical Heart introduced his operate on inflammatory breast most cancers, a type of breast cancer that has a very poor prognosis and responds improperly to treatment. Employing Saphyr, he was ready to recognize recurring structural variants in a gene that was never ever just before related with breast most cancers and may well be a essential variable that defines this aggressive disorder. He concluded that in circumstances like inflammatory breast most cancers exactly where sequencing and other procedures have been fatigued, OGM offers a exclusive option to obtain important variants.
Dr. Eric Letouzé, Cordeliers Investigation Centre, Paris offered on his use of OGM to identify the precise construction of advanced genomic rearrangements in liver cancer, which he was not able to do with complete genome sequencing. He concluded that Saphyr uncovered 50% additional structural rearrangements than NGS, was in a position to unravel sophisticated rearrangements and may perhaps be applied to determine replication pressure in scientific samples, which could identify if clients can be addressed with the extremely effective PARP inhibitor medicine.
David Gentien, Supervisor of the Genomics System, Curie Institute, Paris introduced his analyze with OGM of uveal melanoma, a most cancers of the eye that can be very intense when it metastasizes. Applying Saphyr, he identified distinctive styles of structural variants that made various gene fusions considered to outline this tumor sort and that have been skipped by entire genome sequence and other molecular solutions.
Dr. Ravindra Kolhe, Vice-Chairman of Pathology at the Clinical University of Ga at Augusta University explained his development in producing a laboratory made check (LDT) for solid tumor with Saphyr. Preliminary effects from his examine on the to start with five glioblastoma samples showed 100% concordance amongst OGM and the present workflow for solid tumor screening in his laboratory, the Oncoscan SNP array system put together with 5 locus particular tests using a number of various tactics. Dr. Kolhe concluded that Saphyr outperformed the Oncoscan array by detecting 100% of the variants located by the array system and lots of far more clinically actionable gatherings it missed, and that Saphyr better characterised complicated functions. In addition to the greater effectiveness, Saphyr has decreased palms-on time, speedier change-close to time, and is price tag successful in comparison to this present blend of methods. He believes that exams made on Saphyr could support in building a much more exact prognosis and could measure remedy reaction.
The symposium carries on Thursday and Friday. The whole agenda of speakers and registration access is obtainable at http://bit.ly/3pLPT28
About Bionano Genomics
Bionano is a genome evaluation firm offering instruments and companies based mostly on its Saphyr method to researchers and clinicians conducting genetic investigation and individual tests and furnishing diagnostic testing for individuals with autism spectrum disorder (ASD) and other neurodevelopmental disabilities via its Lineagen small business. Bionano’s Saphyr procedure is a research use only platform for extremely-sensitive and extremely-certain structural variation detection that enables scientists and clinicians to speed up the research for new diagnostics and therapeutic targets and to streamline the analyze of modifications in chromosomes, which is acknowledged as cytogenetics. The Saphyr program is comprised of an instrument, chip consumables, reagents and a suite of knowledge examination instruments, and genome investigation providers to supply access to details generated by the Saphyr program for scientists who favor not to adopt the Saphyr program in their labs. Lineagen has been giving genetic testing providers to families and their health care providers for around 9 a long time and has performed over 65,000 checks for those people with neurodevelopmental worries. For a lot more details, pay a visit to www.bionanogenomics.com or www.lineagen.com.
Forward-Searching Statements
This press release has ahead-looking statements inside the that means of the Private Securities Litigation Reform Act of 1995. Phrases this kind of as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as properly as other words or expressions referencing upcoming activities, disorders or conditions) express uncertainty of upcoming events or outcomes and are meant to detect these ahead-looking statements. Ahead-searching statements involve statements relating to our intentions, beliefs, projections, outlook, analyses or present-day anticipations concerning, amongst other things: the timing and material of the shows discovered in this press release the performance and utility of Bionano’s technological innovation in fundamental genetic analysis and scientific options, and in the contexts and applications contemplated by the presentations recognized in this press launch adoption of Saphyr as a standard platform in exploration and pathology options and the execution of Bionano’s strategy. Each of these ahead-searching statements requires hazards and uncertainties. Precise final results or developments may well vary materially from all those projected or implied in these forward-wanting statements. Things that may possibly bring about such a distinction include the dangers and uncertainties connected with: the influence of the COVID-19 pandemic on our business and the world wide economy typical current market ailments variations in the competitive landscape and the introduction of competitive products changes in our strategic and commercial plans our skill to get ample financing to fund our strategic ideas and commercialization efforts the capacity of clinical and exploration establishments to obtain funding to assistance adoption or ongoing use of our systems the reduction of important associates of administration and our business staff and the pitfalls and uncertainties connected with our company and financial problem in common, together with the pitfalls and uncertainties described in our filings with the Securities and Exchange Commission, like, with no limitation, our Yearly Report on Variety 10-K for the year ended December 31, 2019 and in other filings subsequently built by us with the Securities and Trade Fee. All forward-on the lookout statements contained in this press launch talk only as of the day on which they ended up produced and are based on management’s assumptions and estimates as of these kinds of date. We do not undertake any obligation to publicly update any ahead-looking statements, whether or not as a outcome of the receipt of new facts, the event of potential occasions or otherwise.
CONTACTS
Company Call:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
[email protected]
Trader Relations Call:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
[email protected]
Media Speak to:
Darren Opland, PhD
LifeSci Communications
+1 (617) 733-7668
[email protected]
